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Abstract
Inadequate antibody responses and perturbed B cell compartments represent hallmarks of 
persistent microbial infections, but the mechanisms whereby persisting pathogens suppress 
humoral immunity remain poorly defined. Using adoptive transfer experiments in the context of a 
chronic lymphocytic choriomeningitis virus (LCMV) infection of mice, we have documented 
rapid depletion of virus-specific B cells that coincided with the early type I interferon response to 
infection. We found that the loss of activated B cells was driven by type I interferon (IFN-I) 
signaling to several cell types including dendritic cells, T cells and myeloid cells. Intriguingly, this 
process was independent of B cell-intrinsic IFN-I sensing and resulted from biased differentiation 
of naïve B cells into short-lived antibody-secreting cells. The ability to generate robust B cell 
responses was restored upon IFN-I receptor blockade or, partially, when experimentally depleting 
myeloid cells or the IFN-I-induced cytokines interleukin 10 and tumor necrosis factor alpha. We 
have termed this IFN-I-driven depletion of B cells “B cell decimation”. Strategies to counter “B 
cell decimation” should thus help us better leverage humoral immunity in the combat against 
persistent microbial diseases.
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Introduction
Humoral immunity represents a cornerstone of antimicrobial host defense and vaccine 
protection. Conversely, perturbed or dysfunctional B cell compartments constitute a 
hallmark of persistent microbial diseases including HIV, hepatitis B, hepatitis C, malaria, 
schistosomiasis and tuberculosis (1–5). Besides delayed and inadequate antibody responses 
to the causative agent itself (6, 7), consequences can consist in a generalized suppression of 
vaccine responses and B cell memory (8–10). In comparison to T cell exhaustion, however, 
the molecular mechanisms leading to viral subversion of the B cell system are less well 
understood.
Elevated expression levels of type I interferon (IFN-I) stimulated genes (ISGs) have been 
observed in chronic hepatitis C virus infection and chronic active tuberculosis, and have 
been shown in immunodeficiency virus infection to correlate with progression to AIDS (11–
14). Besides its essential role in antiviral host defense, IFN-I can apparently exert 
detrimental effects on antiviral T cell responses (15, 16). Conversely, a potential impact of 
IFN-I on B cell responses to chronic infection has remained ill-defined.
Chronic lymphocytic choriomeningitis virus (LCMV) infection of mice is widely used to 
study immune subversion in persistent infection. Delayed and weak neutralizing antibody 
(nAb) responses alongside with T cell exhaustion represent characteristic features of this 
model as well as of human HIV and hepatitis C virus infection (6, 7). The LCMV envelope 
carries a glycan shield as a structural mechanism of nAb evasion (17, 18). Additionally, CD8 
T cells, NK cells as well as inappropriate T cell help have been proposed to delay nAb 
formation to LCMV infection (19–22). In contrast, vesicular stomatitis virus (VSV) 
represents a prototypic acute infection, which triggers a rapid and potent nAb response (17).
Here we report that IFN-I-induced inflammation at the onset of chronic LCMV infection 
triggers unsustainable plasmablast responses, culminating in the depletion of virus-specific 
B cells. Mechanistic insights into this process should provide a conceptual basis to refine 
vaccination efforts and counter humoral immune subversion in persistent microbial diseases.
Results
Depletion of virus-specific B cells at the onset of rCl13 but not rVSV infection
Here we compared B cell responses to protracted LCMV infection (rCl13) and to 
recombinant vesicular stomatitis virus (rVSV) vaccine vectors. The two viruses were 
engineered to express the same surface glycoprotein (GP) as neutralizing antibody target, but 
served as prototypic models of chronic viremic and acute infection, respectively (Fig. 1A). 
To study antiviral B cell responses in mice, we adoptively transferred oligoclonal, traceable 
(CD45.1+) KL25H B cells, which contain ~2% GP-specific cells owing to an 
immunoglobulin heavy chain knock-in (Fig. S1A). The transferred KL25H cells mounted 
only transient GP-specific antibody responses to rCl13, whereas rVSV infection induced 
sustained responses of higher titer (Fig. 1B). Moreover, KL25H B cell numbers at four 
weeks after rVSV immunization were ~20-fold higher than after rCl13 infection (Fig. 1C). 
We obtained analogous results, both in spleen and inguinal lymph nodes (iLN), when 
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adoptively transferring quasi-monoclonal KL25HL B cells (~85% GP-specific, Fig. S1A, B), 
which express the matching immunoglobulin light chain transgene in addition to the heavy 
chain knock-in (Fig. 1D, S1C). Four weeks after infection, KL25HL B cells populated the 
germinal centers (GCs) of rVSV-immunized mice but not of rCl13-infected animals (Fig. 
1E). When studying (CD45.1+ donor) KL25HL B cells in the first week of rCl13 infection, 
they proliferated and were enlarged in shape, but they declined in numbers already on day 3 
and disappeared almost completely by day 6 (Fig. 1F, G, S1D). On day three, the majority of 
proliferating (CFSElow) KL25HL B cells in rCl13-infected mice were apoptotic 
(7AAD+AnnexinV+, Fig. 1H), whereas KL25HL B cells responding to rVSV remained 
mostly viable albeit proliferating at a comparable rate (Fig. 1G).
B cell “decimation” correlates with the time point of cell transfer rather than with antigen 
load
These observations suggested a near-complete apoptotic loss (referred to as “decimation”) of 
virus-neutralizing KL25HL B cells within days after the onset of rCl13 infection. By 
analogy to T cells (23), high antigen loads in rCl13 but not rVSV infection could have 
accounted for antiviral B cell decimation. Counter to this hypothesis, adoptive transfer of 
KL25HL B cells into neonatally infected immunologically tolerant rCl13 carrier mice (24) 
resulted in robust B cell and plasmablast/plasma cell (antibody-secreting cell, ASC) 
formation despite high-level viremia (Fig. 2A and S2A, S2B; B cells and ASCs jointly 
referred to as “B cell progeny”). Furthermore, KL25HL B cell transfer on day 3 of rCl13 
infection, when viremia had set in, yielded ~20-fold more B cell progeny than transfer at the 
onset of infection (Fig. 2B, C (22)). Day 3 transfer of KL25HL B cells resulted also in 
substantially higher neutralizing antibody (nAb) responses and in a more potent antiviral 
effect than transfer on the day of infection (Fig. 2D, E). These observations argued against 
antigen overload as the root cause of KL25HL B cell decimation, suggesting rather that the 
inflammatory milieu at the onset of infection was unfavorable to sustained B cell responses.
Type I interferon receptor blockade restores B cell expansion and GC B cell differentiation 
in rCl13 infection
Intriguingly, this 3-day time window coincided with the strong systemic type I interferon 
(IFN-I) response in rCl13 infection (Fig. 3A). Moreover, rCl13-induced serum IFN-I 
responses clearly exceeded those induced by rVSV, and IFN-I was below technical 
backgrounds in rCl13 carriers, altogether suggesting an inverse correlation between systemic 
IFN-I levels and sustained antiviral B cell responses. Hence we speculated that rCl13-
induced IFN-I accounted for antiviral B cell decimation. Antibody-based blockade of the 
type I interferon receptor (αIFNAR) resulted in ~20-fold more KL25HL progeny on day 3 
of rCl13 infection (Fig. 3B, C). By day 15, IFNAR blockade yielded >100-fold higher 
numbers of GL7– (non-GC) KL25HL B cells and GL-7+ (GC) B cells, both in spleen and 
iLN, and comparably elevated KL25HL progeny were found in bone marrow (BM, Fig. 3D 
and S3A). By immunohistochemistry we detected KL25HL B cells in GCs of IFNAR-
blocked mice but not of control-treated animals (Fig. 3E). To investigate whether also 
antigen-experienced B cells were sensitive to IFN-I-driven decimation, we expanded KL25H 
B cells in vivo and transferred them to naïve recipients, followed by rCl13 challenge (see 
Fig. S3B for set-up). The transferred cell population was largely antigen-specific (~50% GP-
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binding) and comprised GL7+ (GC) as well as GL7– cells but virtually no ASCs (Fig. S3C, 
D). IFNAR blockade yielded significantly more KL25H PCs and B cells on day 8 and day 
67 after rCl13 challenge, respectively (Fig. 3F and S3E). Performing immunohistochemistry 
on day 67, we readily detected KL25H B cells in GCs of IFNAR-blocked but not control-
treated recipients (Fig. 3G). While it cannot be determined at this point, whether the GL7+ 
or GL7– subset of antigen-experienced B cells or both were rescued by αIFNAR, neither 
subset formed substantial progeny upon rCl13 challenge unless IFNAR was blocked. We 
extended these adoptive transfer experiments to polyclonal LCMV-experienced B cells of 
GFP-transgenic ubc-gfp mice (see Fig. S3F for set-up). On day 7 after rCl13 challenge, 
IFNAR-blocked recipients contained ~30-fold higher numbers of LCMV nucleoprotein (NP) 
-binding GFP+ B cell progeny than control-treated animals (Fig. 3H and S3G). Altogether, 
this documented that not only primary responses of LCMV-specific KL25H and KL25HL B 
cells but also recall responses of antigen-experienced LCMV-specific B cells, both 
oligoclonal (KL25H) and polyclonal, were subject to IFN-I-driven decimation. Infection 
with rCl13 variants (25) exhibiting 6-fold and 30-fold lower affinity for KL25, respectively, 
yielded similarly low KL25HL progeny numbers as rCl13, and all responses reached 
comparable levels when rescued by IFNAR blockade (Fig. S4A). This suggested that B cells 
of lower affinity could also be subject to IFN-I-driven decimation. Next we tested whether B 
cells of unrelated specificity, when activated concomitantly with rCl13 infection (“activated 
bystander B cells”), were similarly affected. We transferred traceable (CD45.2+) VI10 heavy 
chain knock-in B cells containing ~15% vesicular stomatitis virus glycoprotein (VSVG) -
specific B cells (26) into syngeneic (CD45.1+) wt recipients. Subsequent immunization with 
VSVG triggered robust proliferation (CFSE dilution) and expansion of virtually all VSVG-
binding VI10 B cells. This response was markedly reduced by concomitant rCl13 infection 
but completely rescued by αIFNAR, extending the concept of IFN-I-driven decimation to 
activated bystander B cells (Fig. 3I). The use of (non-replicating) VSVG protein in these 
experiments corroborated that cognate antigen loads could not readily explain rCl13-driven 
B cell decimation. Moreover, rCl13 infection did not decimate VSVG-binding VI10 cells 
when concomitant VSVG immunization was omitted (Fig. S4B), suggesting that B cell 
receptor signaling was required for decimation.
IFN-I-induced short-lived plasmablast differentiation in rCl13 infection
αIFNAR prevented KL25HL B cell apoptosis as determined by flow cytometry (AnnexinV/
7AAD binding) and by active caspase-3 staining in histology (Fig. 4A-C). To better 
understand IFN-I-driven B cell decimation, we performed whole genome RNA sequencing 
on KL25HL B cells recovered on day 3 of rCl13 infection. A pronounced antibody-secreting 
cell signature (27) was observed in control-treated cells, illustrated by the upregulation of 
prdm1 (encoding BLIMP1), sdc1 (encoding CD138), irf4 and xbp1, and the downregulation 
of pax5, bcl6, cxcr5, cd38 and cd19 expression, which were largely reversed by IFNAR 
blockade (Fig. 4D and S5A). This effect was also evident in αIFNAR-mediated suppression 
of ASC-related transcription factors (TF, Fig. S5B). Conversely, IFNAR blockade promoted/
restored TF expression profiles, which are typical for mature B cell stages prior to ASC 
differentiation (Fig. S5C). In line with its effects on the cells’ ASC gene signature, αIFNAR 
altered the expression of 10 out of 13 genes, which have been linked to terminal B cell 
differentiation in human HIV infection (Fig. S5D, (28)). Flow cytometric analyses 
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corroborated that IFNAR blockade impeded rCl13-induced ASC differentiation. As 
hallmarks of ASC differentiation, most KL25HL B cells in control-treated recipients lost 
B220, CD22 and CD23 expression as they proliferated (Fig. 4E). When IFNAR was 
blocked, a significantly higher proportion of KL25HL progeny cells retained these markers. 
Conversely, fewer KL25HL cells up-regulated the ASC marker CD138, and their 
intracellular IgM levels were lower (Fig. 4E). Altogether these observations indicated that 
IFNAR blockade prevented specific B cell decimation by countering short-lived plasmablast 
differentiation. In keeping with this interpretation, IFNAR blockade resulted in lower NP-
specific IgM titers on day 4 after infection, but in higher IgG responses on day 8 (Fig. 4F).
Decimation results from IFN-I effects on hematopoietic cells other than B cells, and is due 
to inflammation including IL-10 and TNF-α
To differentiate between B cell-intrinsic and –extrinsic IFNAR effects on B cell decimation 
we used IFNAR-deficient and –sufficient KL25HL B cells for adoptive transfer. Both B cell 
types expanded vigorously when challenged with rCl13 in ifnar-/- recipients but yielded low 
progeny numbers when responding in wt recipients (Fig. 5A). This suggested B cell-
extrinsic IFN-I effects as the root cause of rCl13-induced B cell decimation. We extended 
these observations to activated bystander B cells. IFNAR-deficient and –sufficient VI10 B 
cells responded similarly to VSVG protein immunization, and both responses were equally 
suppressed by concomitant rCl13 infection (Fig. 5B). When using reciprocal wt and ifnar-/- 
BM chimeras as recipients we found that hematopoietic IFNAR expression was sufficient 
for KL25HL B cell decimation (Fig. 5C). The comparison of ifnar-/-→ifnar-/- and 
ifnar-/-→wt chimeras suggested an additional albeit modest impact of non-hematopoietic 
IFNAR on ASC numbers. To dissect how IFNAR signaling in various immune cell types 
contributed to B cell decimation we exploited cell type-specific IFNAR deletion models. 
KL25HL B cell progeny were significantly more numerous when recipients lacked IFNAR 
in either T cells (ifnarfl/fcd4-cre), dendritic cells (ifnarfl/lfcd11c-cre) or myeloid cells 
(ifnarfl/flLysM-cre). IFNAR deletion in the recipient’s B cells (ifnarfl/flcd19-cre) only 
modestly augmented KL25HL ASCs, and neither of the above cell-type specific IFNAR 
deletion models fully phenocopied plain ifnar-/- recipients (Fig. 5D). While the fidelity of 
these tissue-specific Cre deletion models has limitations, these data suggested that B cell 
decimation resulted from IFNAR signaling to several cell types such as myeloid cells, T 
cells and DCs. The essential antiviral role of IFN-I may preclude the success of αIFNAR-
based immunomodulatory therapy ((15, 16, 29), Fig. S6A). Also T cells and DCs are widely 
recognized as essential components of antiviral immune defense, but inhibition or depletion 
of myeloid cells can be pursued to combat persistent infection and cancer (30, 31). Hence 
we tested whether, by analogy to myeloid cell-specific IFNAR deficiency, myeloid cell 
depletion could rescue KL25HL B cell responses. Albeit less dramatically than αIFNAR, 
also αGr-1 (Ly6C/G) antibody depletion, a widely used means to deplete myeloid cells in 
mice, augmented KL25HL progeny (Fig 5E). Of note, αGr-1 depletion did not substantially 
affect viral loads or serum IFN-I kinetics (Fig. S6A, B), attesting to the potential utility of 
myeloid cell-targeting strategies for countering B cell decimation. In accordance with earlier 
reports, however, αGr-1 depleted not only inflammatory monocytes (InfMo) and neutrophils 
but also eosinophils, plasmacytoid dendritic cells (pDCs) and Ly6Chigh CD8+ T cells (Fig. 
S6C, D). Yet, the individual depletion of neutrophils, eosinophils or pDCs did not increase 
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KL25HL B cell progeny, and cd8-/- mice yielded only modestly elevated numbers of 
KL25HL ASCs (Fig. S6E). αCD8 antibody depletion exerted a more pronounced effect (19) 
albeit not phenocopying IFNAR blockade either, and the depletion of CD8α+ DCs (32) may 
have contributed to this B cell sparing effect (Fig. S6F). CD4 T cell depletion or NK cell 
depletion did not augment KL25HL progeny, and αIFNAR restored KL25HL B cell 
responses also in CD4+ T cell-depleted mice (Fig. S6F, G), suggesting that IFN-I-driven B 
cell decimation was not directly related to IFN-I and NK cell effects on T follicular helper 
cell responses (20, 33). To address a potential role of InfMo in B cell decimation we used 
both InfMo-deficient ccr2-/- and klf4fl/flxVav1-icre recipients (Fig. S6H-K and (34)). Neither 
model phenocopied the αGr-1 effect, and αGr-1 depletion improved KL25HL progeny 
recovery also in InfMo-deficient ccr2-/- recipients (Fig S6K). Hence, the B cell-sparing 
effect of αGr-1 depletion likely represented its combined impact on multiple myeloid and 
perhaps even non-myeloid cell subsets. Thus we speculated that both αGr-1 and αIFNAR 
countered antiviral B cell decimation by altering virus-induced inflammation. When 
profiling the expression of 248 inflammation-related genes in spleen, 128 were altered upon 
rCl13 infection, and αIFNAR attenuated or prevented a majority of these inflammatory gene 
expression changes (Fig. 5F, S7A B, Tbl. SI). αGr-1 also exerted clear albeit less wide-
ranging effects, and a majority of αGr-1-mediated gene expression changes such as in oasl1, 
ifit2, ifit3 and il10 were also covered by αIFNAR (17/25=69% in spleen; 13/17=76% in 
BM, Fig. S7C, D, Tbl, SI). In a serum cytokine panel analysis, 19 out of 31 tested 
chemokines and cytokines increased at 24 and 72 hours after rCl13 infection, respectively, 
and were at least 4-fold suppressed by αIFNAR (Fig. 5G, Table. SII). Eight of these 19 were 
also significantly suppressed, albeit less potently, in αGr-1-treated animals (red bars in Fig. 
5G). Taken together, IFNAR deficiency and, to a lesser extent also αGr-1, modulated rCl13-
induced systemic inflammation, and most αGr-1 effects on inflammation were comprised in 
the αIFNAR effects. These observations raised the possibility that the IFN-I-induced 
inflammatory milieu in rCl13 infection caused B cell decimation by altering B cell survival 
and/or differentiation signals. This hypothesis predicted that i) the supplementation of 
survival signals and also ii) the depletion of deleterious inflammatory mediators or blockade 
of death pathways should augment specific B cell responses in rCl13 infection. In line with 
prediction i), KL25HL B cell transfer and rCl13 infection yielded ~10-fold more progeny 
when performed in transgenic recipients artificially overexpressing the B cell survival factor 
BAFF (Fig. S8A). In attempting to test prediction ii) we used knock-out mouse models and 
antibody depletion approaches to assess the individual contribution of IL-1β, IL-4, IL-6, 
IL-10, IL-12, TNF-α, iNOS and FasL to rCl13-induced KL25HL B cell decimation. 
KL25HL B cells yielded significantly more progeny when challenged with rCl13 in IL-10-
deficient or TNF-α-blocked recipient mice (Fig 5H, I). While we failed to detect a 
statistically significant individual role for IL-1β, IL-4, IL-6, IL-12, iNOS or FasL in B cell 
decimation (Fig. S8B-E), contributive effects of some of these and other IFN-I-induced 
factors and pathways (28, 35, 36) remain likely. Accordingly, only their combined 
suppression alongside with IL-10 and TNF-α may account for the potent B cell-sparing 
effect of IFNAR blockade.
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Discussion
IFN-I driven B cell decimation may reflect the immune system’s attempt at maximizing 
early antibody production in a highly inflammatory context. In acute life-threatening 
infections, this ASC differentiation bias may augment survival chances by maximizing early 
immunoglobulin production and seems desirable from an evolutionary standpoint. 
Conversely, B cell decimation puts at risk the sustainability of humoral responses, both of 
naïve and immunized hosts, when confronted with persistence-prone pathogens.
Repertoire replenishment by new bone marrow emigrants (22, 37) and GC-driven evolution 
of low-affinity clones are predicted to eventually compensate for early repertoire decimation. 
These processes are thus likely to have supplied the B cells, which eventually formed GCs in 
rCl13-infected mice even when IFNAR signaling was intact (Figs. 1E, 3E, G). The sustained 
IFN-I transcriptome signatures in active tuberculosis, chronic hepatitis C virus and 
pathogenic immunodeficiency virus infection raise the possibility that B cell decimation 
extends into the chronic phase of infection (11–14) and may have long-term effects on B cell 
responses and memory (6, 8–10). While IFN-I warrants the host’s survival in the acute phase 
of infection (29), persisting IFN-I-driven inflammation may thus paradoxically promote 
microbial evasion of humoral immunity in the chronic disease context.
Unlike IFN-I transcriptome signatures, which represent a common characteristic of many 
persistent microbial infections, individual IFN-I induced inflammatory mediators and their 
impact on immune responses can vary between infection settings. IFN-I-induced IL-10 and 
myeloid cells, for example, are known to regulate cellular immunity to LCMV in a virus 
strain- and load-dependent manner (15, 31, 38). It thus seems noteworthy that IL-10 as well 
as TNF-α, which we identify as mediators of IFN-I-driven B cell decimation, have 
previously been linked to B cell dysfunction in HIV-1 infection (35, 39). DCs represent a 
main sources of IL-10 in chronic LCMV infection (15), offering a potential mechanism for 
these cells’ contribution to IFN-I-driven B cell decimation.
While our work would have been technically challenging without the development of BCR-
engineered mice, we acknowledge that the use of this tool is a limitation of our study. The B 
cell receptor in question exhibits high affinity for GP and only a narrow range of lower-
affinity GP variants could be tested, and limitation of the available flow cytometric 
methodology rendered detection of endogenous GP-specific B cells unreliable. Further, the 
majority of the work was focused on B cell responses to the GP as sole antigen, and the 
characterization of “decimated” B cell populations required the adoptive transfer of large 
numbers of receptor-engineered naïve B cells, well above their normal frequencies in the B 
cell repertoire of a naïve mouse. Finally, while we have provided several independent lines 
of evidence supporting the essential role of IFN-I in B cell decimation, it remains to be 
investigated whether IFN-I is sufficient to trigger this process.
In conclusion, IFN-I-driven B cell decimation offers a molecular mechanism for humoral 
immune subversion under conditions of persistent microbial inflammation. Our studies 
highlight the contributions of several immune cells and cytokines to B cell decimation, and 
these insights should be helpful in refining vaccination efforts against persisting pathogens.
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Materials and Methods
Viruses, virus titrations, infections and immunizations
LCMV strain Clone 13 expressing the LCMV strain WE glycoprotein (rCl13) and variants 
thereof containing either the N121K or N119D mutations (25) in GP, respectively, were 
engineered as described (40). A recombinant vesicular stomatitis virus vector expressing the 
LCMV strain WE glycoprotein instead of VSVG (rVSV) was generated following 
established procedures and strategies (41). rCl13 and rVSV were grown on BHK-21 cells 
and were titrated as described (17). Unless specified otherwise, rCl13 and rVSV were 
administered to mice intravenously (i.v.) at doses of 2x106 and 8x106 plaque-forming units 
(PFU), respectively. Adult infections were performed 30 min. after adoptive B cell transfer. 
Neonatal infections were performed with 6x105 PFU rCl13 into the skull within 24 hours 
after birth. VSV glycoprotein (VSVG) for immunization was produced in SF9 cells using a 
recombinant baculovirus system (17). 20 µg whole cell lysate was administered to mice i.v..
Flow cytometry and FACS sorting
To prepare single cell suspensions, tibiae were flushed and spleens were enzymatically 
digested using collagenase D (Roche) and DNAseI (Sigma-Aldrich). Cell media were 
adjusted to mouse osmolarity. Staining reagents and procedures are reported in 
Supplementary Materials. Labelled cells were measured on Gallios (Beckman Coulter) and 
LSRFortessa (Becton Dickinson) flow cytometers. Data were analyzed using FlowJo 
software (Tree Star). FACS sorting of KL25HL B cells progeny was performed directly into 
TRI Reagent LS (Sigma-Aldrich) using an FACSAria II (Becton Dickinson, BD) cell sorter. 
RNA was extracted using the Direct-zol™ RNA MicroPrep kit (Zymo research).
Immunohistochemistry and image analysis
Tissues were fixed in HEPES-glutamic acid buffer-mediated organic solvent protection 
effect (HOPE, DCS Innovative) fixative as previously described (42) and embedded in 
paraffin. Immunostaining was performed on 3 µm thick sections using antibodies against 
active caspase-3 (9661T, Cell Signaling) and CD45.1 (clone A20, FITC-labeled, 
BioLegend). Bound caspase-3 antibodies were visualized using tyramide signal 
amplification (Thermo-Fisher). Bound CD45.1 antibodies were visualized using rabbit anti-
FITC antibody followed by incubation with Alexa-fluor goat-anti-rabbit antibody (Life-
Technologies). Germinal centers were visualized using FITC-labeled Peanut agglutinin 
(PNA; Life technologies). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, 
Invitrogen). Image processing and analysis are described in Supplementary Methods.
Whole-genome RNA sequencing and low-density inflammatory gene expression profiling
For RNA sequencing of sorted KL25HL B cells, RNA was extracted using the Direct-zol™ 
RNA MicroPrep kit (Zymo research). Libraries were prepared using the TruSeq kit 
(Illumina) and sequencing was performed by 50 bp single-end reads on an Illumina HiSeq 
2000.
For low-density inflammatory gene expression profiling, spleen and BM RNA was extracted 
using Direct-zol™ RNA MicroPrep kit (Zymo research). Expression profiling was done 
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using the nCounter Nanostring Mouse Inflammation v2 assay (NanoString Technologies). 
Statistical analysis of gene expression profiles is described in Supplementary Methods.
Mice and animal experiments
To generate KL25L transgenic mice, the expression cassette described in Fig. S1B was 
released from its vector and was injected into C57BL/6 embryos using standard techniques. 
Sources and references of previously published mouse lines as well as intercrosses are 
detailed in Supplementary Materials and Methods. All mice were kept under specific-
pathogen-free (SPF) conditions for colony maintenance and experiments. Experiments were 
performed at the Universities of Geneva and Basel, in accordance with the Swiss law for 
animal protection and with authorization by the respective Cantonal authorities.
Adoptive cell transfer and fluorescent cell labeling
For adoptive transfer of naïve B cells and subsequent analysis by flow cytometry, splenocyte 
suspensions (2-4x106 per recipient) in balanced salt solution were administered i.v. For 
histological assessments, MACS-purified B cells (Miltenyi Biotec Pan B cell isolation kit, 
for untouched B cells) were also used. Syngeneic C57BL/6J mice served as recipients, 
except for long-term (>1 week) transfer of KL25HL cells, which were performed in KL25L 
recipients to avoid anti-idiotypic responses. To assess in vivo proliferation, splenocyte 
populations were labeled with Carboxyfluorescein succinimidyl ester (CFSE, Sigma-
Aldrich) or CellTraceViolet (CTV, Life Technologies). The generation of antigen-
experienced B cells for adoptive transfer is detailed in Supplementary Materials and 
Methods.
Antibody, interferon-α and cytokine/chemokine panel measurements
GP-1-binding antibodies were measured as described (43). To discriminate responses of 
adoptively transferred KL25H B cells from endogenous responses in ELISA, background 
GP-1 antibody titers in control mice without KL25H cell transfer were determined and were 
subtracted.
rCl13-neutralizing antibodies (nAbs) were measured by immunofocus reduction assays (17). 
IFN-α concentrations in serum were determined using the VeriKine Mouse Interferon Alpha 
ELISA Kit (PBL Assay Science). To profile inflammatory responses in mouse serum we 
used a laser bead-based 31-plex cytokine and chemokine array (Eve Biotechnologies).
Statistical analysis
For comparison of one parameter between two groups, unpaired two-tailed Student’s t tests 
were performed. One-way analysis of variance (ANOVA) was used to compare one 
parameter between multiple groups, two-way ANOVA for comparison of multiple 
parameters between two or more groups. ANOVA was followed by Bonferroni’s post-test 
for multiple comparisons. Dunnett’s post-test was used to compare multiple groups to a 
control group. With the exception of percentages, values were log-converted to obtain a 
near-normal distribution for statistical analysis. Data were analyzed using Graphpad Prism 
software (version 6.0h). P values >0.05 were considered not significant (ns), p values <0.05 
were considered significant (*,#) and p values <0.01 highly significant (**,##).
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Data and materials availability
RNAseq and low-density gene expression profiling data are deposited with the National 
Center for Biotechnology Information Gene Expression Omnibus (GEO, accession numbers 
GSE84037 and GSE84036 respectively).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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One-sentence summary
Interferon-driven inflammation in chronic viral infection orchestrates unsustainable B 
cell response.
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Fig. 1. Depletion of virus-specific B cells at the onset of rCl13 but not rVSV infection.
A: We infected wt mice with rCl13 or rVSV and measured viremia on the indicated days.
B-H: We adoptively transferred KL25H (B,C) or KL25HL cells (D-H) into naïve syngeneic 
recipients, followed by rCl13 or rVSV challenge. On the indicated days, KL25H-derived 
GP1-binding IgG were determined (B). Progeny B cells were enumerated by flow cytometry 
in spleen and iLN (C,D). KL25HL B cells (CD45.1+) in germinal centers (E, bar 100 µm) 
and their abortive expansion following rCl13 infection (F, magnification bar 50 µm, inset 20 
µm) by histology. Proliferation (CFSE dilution) of d3 rCl13- and rVSV-challenged KL25HL 
B cells, gated on CD45.1+B220+ lymphocytes (G; background proliferation of 
CD45.1+B220+ lymphocytes in uninfected controls was 1.2±0.2 % (mean±SEM), not 
displayed). Apoptotic (AnnexinV+/7AAD+) KL25HL B cells on d3 of rCl13 or rVSV 
challenge, gated on CD45.1+B220+CFSElo lymphocytes (H). Gating is shown in Fig. S1C. 
Numbers in FACS plots indicate percentages (mean±SEM). Symbols and bars represent 
mean±SEM. Number of biological replicates (n) =3-4 (A-C), n=4 (D-F), n=3 (G,H). 
Number of independent experiments (N) =2. Unpaired two-tailed Student’s t tests (C-D,G), 
two-way analysis of variance (ANOVA) with Bonferroni’s post-test for multiple 
comparisons (B,H). ns: not significant; *: p<0.05; **: p<0.01.
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Fig. 2. B cell “decimation” correlates with the time point of cell transfer rather than with antigen 
load
A: We adoptively transferred KL25HL cells into neonatally infected rCl13 carriers or adult 
rCl13-infected mice on d0 and measured B cell proliferation and progeny (B cells and 
ASCs) on day 3 in spleen.
B-E: Upon KL25HL transfer and rCl13 infection, timed as outlined (B), we measured 
KL25HL B cell proliferation and expansion (C), nAb responses (D) and viremia (E). 
Numbers in FACS plots indicate percentages (mean±SEM). FACS plots are gated on 
CD45.1+B220+ lymphocytes. B cell and ASC gating is shown in Fig. S2A. Symbols and 
bars represent mean±SEM. n= 3, N=2 (A), N=3 (C-E). Two-way ANOVA with Bonferroni’s 
post-test for multiple comparisons (A,C). **,##: p<0.01; ** compares B cells; ## compares 
ASCs.
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Fig. 3. IFNAR blockade restores B cell expansion and GC B cell differentiation in rCl13 
infection.
A: Serum IFN-α in KL25HL cell recipients, infected with rCl13 at birth or on d0, or 
infected with rVSV on d0.
B-H: We transferred naïve KL25HL cells (B-E), antigen-experienced KL25H B cells (F-G) 
or antigen-experienced polyclonal GFP+ B cells (H) to αIFNAR- or control-treated wt 
recipients, followed by rCl13 infection (see Figs. S3B-D and and S3F for experimental 
design and characterization of transferred cells). B cell progeny in the indicated organs were 
detected by FACS (B,D,F,H) and histology (C,E,G). Note progeny of naïve KL25HL cells 
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(E) and of antigen-experienced KL25H cells (G) in GCs of IFNAR-blocked recipients. 
Magnification bars: 50 µm, inset 20 µm (C); 200 µm (E); 100 µm (G). Numbers in (H) 
represent LCMV-NP-binding (see Fig. S3G), proliferated (CellTraceViolet/CTVlo) 
polyclonal donor (GFP+) B cell progeny (CTVloGFP+LCMV-NP+) lymphocytes. (gating 
shown in S2A for B, F and S3A for D)
I: We transferred naïve VI10 cells to αIFNAR- or control-treated recipients, followed by 
VSVG immunization, alone or in combination with rCl13 infection. Proliferated (CFSElo) 
VSVG-binding VI10 B cells were enumerated by FACS. Plots are gated on CD45.2+B220+ 
lymphocytes, numbers indicate percentages. Symbols and bars represent mean±SEM. n=3-4 
(A,F), n=3 (D), n=4 (B,C,E,G-I). N=2-3 (F), N=2 (A,C-E,G), N=3 (B,H,I). Two-way 
ANOVA with Bonferroni’s post-test for multiple comparisons (A,B,D,F), unpaired two-
tailed Student’s t test (H), one-way ANOVA with Bonferroni’s post-test for multiple 
comparisons (I). ns: not significant; *,#: p<0.05; **,##: p<0.01. *,** compare total or GL7+ 
B cells; #,## compare ASCs or GL7- B cells, respectively.
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Fig. 4. IFN-I-induced short-lived plasmablast differentiation in rCl13 infection.
A-D: We transferred naïve KL25HL cells to αIFNAR- or control-treated recipients, 
followed by rCl13 infection and analysis in spleen on day 3. Apoptotic KL25HL B cell were 
identified in FACS based on AnnexinV/7AAD-binding (A) and by histology based on 
expression of active caspase-3 (B,C, magnification bar 50 µm, inset 20 µm). Proliferated 
KL25HL B cell progeny (CD45.1+B220+CFSElo) were FACS-sorted and total RNA was 
processed for RNAseq (D). Heat maps show expression profiles of ASC signature genes 
known to be upregulated (left) or downregulated (right) upon ASC differentiation, 
respectively (27). Each column represents one biological replicate. Self-contained gene set 
testing is shown in Fig. S5A. Plasmablast differentiation of proliferated (CFSElo) KL25HL 
B cell progeny was determined by flow cytometry (E). Numbers in FACS plots indicate the 
percentage of cells falling into the respective gate (A, representative FACS plots, gated as 
shown in Fig. S1C), the percentage of CFSElo cells expressing the respective marker (E) or 
the MFI of cytoplasmic IgM within IgMcyt+CFSElo cells (E, mean±SEM).
F: We infected αIFNAR- or control-treated wt mice with rCl13 and measured NP-binding 
antibody responses. Bars show mean±SEM. n=3 (A), n=3-4 (B,C,E), n=4 (D) and n=4-5 (F). 
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N=2 (A-C,E), N=1 (D,F). Two-way ANOVA with Bonferroni’s post-test for multiple 
comparisons (A), unpaired two-tailed Student’s t test (B,E,F). ns: not significant; *: p<0.05; 
**: p<0.01.
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Fig. 5. Decimation results from IFN-I effects on hematopoietic cells other than B cells, and is due 
to inflammation including IL-10 and TNF-α.
A: We transferred KL25HL cells, either wt or ifnar-/-, into wt or ifnar-/- recipients and 
enumerated splenic KL25HL B cell progeny on d3 after rCl13 infection.
B: We transferred VI10 cells, either wt or ifnar-/-, into wt recipients, followed by VSVG 
immunization and rCl13 infection as indicated, and enumerated splenic VSVG-binding VI10 
B cells on d3.
C-D: We transferred KL25HL cells into reciprocal wt and ifnar-/- BM chimeras (C) or into 
recipients with cell type-specific, conditional or complete IFNAR deficiency (D) and 
enumerated splenic KL25HL B cell progeny on d3 after rCl13 infection.
E: We transferred KL25HL cells into wt recipients, treated with αGr-1, αIFNAR or control 
antibody, and enumerated splenic KL25HL B cell progeny on d3 after rCl13 infection.
F: Low density inflammatory gene expression profiling in spleen of naïve or d3 rCl13-
infected KL25HL recipients. Heat map showing the 48 genes significantly up-regulated 
upon rCl13 infection. Each column represents one biological replicate.
G: Serum chemokines and cytokines were profiled at 24h and 72h after rCl13, respectively. 
ifnar-/- and αGr-1-treated wt mice are expressed as percentage of control-treated wt mice. 
Only those 19/31 profiled chemokines and cytokines are displayed, which were ≥4-fold 
lower in ifnar-/- than wt controls (Tbl. SII). Red bars indicate chemokines/cytokines that 
were suppressed in ifnar-/- and αGr-1-treated mice. Log-converted chemokine and cytokine 
concentrations were used for statistical analysis.
H-I: We transferred KL25HL cells into il-10-/- or wt recipients (H) or into wt recipients, 
treated with αTNF-α or control antibody (I), and enumerated splenic KL25HL B cell 
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progeny on d3 after rCl13 infection. B cells and ASCs were gated as shown in Fig. S2A. 
Bars show mean±SEM. n=3-4 (A), n=3 (B, unimmunized:2, G), n=4 (C,E,H,I) n=3-6 (D), 
n=2-4 (F). N=2 (B,C,I), N=3 (A,D,E,H), N=1 (F,G). ns: not significant; *,#: p<0.05; **,##: 
p<0.01. Two-way ANOVA with Bonferroni’s (A,B,E,H,I,G) or Dunnett’s (C,D) post-test for 
multiple comparisons. *,** compare B cells; #,## compare ASCs.
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